5 Cancer Clinical Trials You May Have Missed

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

Clinical trials are essential for improving cancer treatment, and patients who participate in them receive top-notch care and are closely followed by their team of clinicians.

Patients should discuss the option of clinical trial participation with their health care providers. For those interested in learning more, here are five recent open clinical trials featured in CURE®’s Clinical Trial Corner.

1. Oncolytic Virus Clinical Trial Opens for Patients With Advanced Breast Cancer

Cancer type: metastatic triple-negative breast cancer

This phase 1 clinical trial at City of Hope is a first-in-human study examining CF33-hNIS-anti-PDL1, a genetically engineered oncolytic virus, for patients with metastatic triple-negative breast cancer.

2. First Patient Randomized in Phase 2 Trial for NSCLC Treatment

Cancer type: HLA-A2—positive, metastatic non-small cell lung cancer

This phase 2 trial is investigating second-line Tedopi and Opdivo (nivolumab) in certain patients with lung cancer. Tedopi is a vaccine that researchers are hoping will help optimize the response patients have to Opdivo.

3. CAR-T Cell Therapy Trial Currently Enrolling Patients With CLL and SLL

Cancer type: relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

JCAR017 is a CAR-T cell therapy being investigated in the ongoing TRANSCEND CLL 004 trial. The researchers hope that it can be a promising option for patients who do not achieve a successful response with other options.

4. First Patient Receives Novel Immunotherapy in Bladder Cancer Sub-Study

Cancer type: resectable and/or metastatic bladder cancer that is not eligible for chemotherapy

Researchers have begun investigating neoadjuvant PVSRIPO, an investigational intratumoral viral immunotherapy, with or without checkpoint inhibitors in patients with bladder cancer who are not eligible for chemotherapy. The LUMINOS-103 study is planned to occur in 10 locations across the United States.

5. BOLD-100 Trial Receives FDA Clearance for Treatment of Advanced GI Cancers

Cancer type: advanced gastric, pancreatic, colorectal and bile duct cancer

The BOLD-100-001 trial is aimed to analyze the safety and effectiveness of BOLD-100 plus FOLFOX chemotherapy in patients with advanced gastric, pancreatic, colorectal and bile duct cancers.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.